BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9191622)

  • 1. Propionyl-L-carnitine for intermittent claudication.
    Deckert J
    J Fam Pract; 1997 Jun; 44(6):533-4. PubMed ID: 9191622
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
    Hiatt WR; Creager MA; Amato A; Brass EP
    J Cardiopulm Rehabil Prev; 2011; 31(2):125-32. PubMed ID: 20861750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new therapeutic proposal for intermittent claudication. Propionyl-L-carnitine: new indications concerning mechanism of action].
    Brevetti G; Martone VD; Corrado S; Silvestro A; Di Donato AM; Di Iorio A
    Minerva Cardioangiol; 1998 Sep; 46(9):299-300. PubMed ID: 10021852
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A; De Martini D; Flore R; Gaetani E; Gasbarrini A; Gerardino L; Pola R; Santoliquido A; Serricchio M; Tondi P; Nolfe G
    Drugs Exp Clin Res; 1999; 25(1):29-36. PubMed ID: 10337502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.
    Andreozzi GM
    Expert Opin Pharmacother; 2009 Nov; 10(16):2697-707. PubMed ID: 19827991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication.
    Andreozzi GM; Leone A; Laudani R; Martin R; Deinit G; Cataldi V
    Angiology; 2008; 59(1):84-9. PubMed ID: 18319227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of propionyl-L-carnitine on quality of life in intermittent claudication.
    Brevetti G; Perna S; Sabba C; Martone VD; Di Iorio A; Barletta G
    Am J Cardiol; 1997 Mar; 79(6):777-80. PubMed ID: 9070558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European multicenter study on propionyl-L-carnitine in intermittent claudication.
    Brevetti G; Diehm C; Lambert D
    J Am Coll Cardiol; 1999 Nov; 34(5):1618-24. PubMed ID: 10551714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease.
    Barker GA; Green S; Askew CD; Green AA; Walker PJ
    Med Sci Sports Exerc; 2001 Sep; 33(9):1415-22. PubMed ID: 11528327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment options in intermittent claudication: the US experience.
    Hiatt WR
    Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.
    Hiatt WR; Regensteiner JG; Creager MA; Hirsch AT; Cooke JP; Olin JW; Gorbunov GN; Isner J; Lukjanov YV; Tsitsiashvili MS; Zabelskaya TF; Amato A
    Am J Med; 2001 Jun; 110(8):616-22. PubMed ID: 11382369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
    Riccioni C; Sarcinella R; Palermo G; Izzo A; Liguori M; Koverech A; Messano M; Virmani A
    Int Angiol; 2008 Jun; 27(3):253-9. PubMed ID: 18506129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carnitine and peripheral arterial disease.
    Hiatt WR
    Ann N Y Acad Sci; 2004 Nov; 1033():92-8. PubMed ID: 15591006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
    Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
    Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
    Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
    Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report.
    Gasbarrini G; Mingrone G; Giancaterini A; De Gaetano A; Scarfone A; Capristo E; Calvani M; Caso V; Greco AV
    Hepatogastroenterology; 2003; 50(53):1385-9. PubMed ID: 14571743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
    Kieffer E; Bahnini A; Mouren X; Gamand S
    Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-carnitine.
    Med Lett Drugs Ther; 2004 Nov; 46(1196):95-6. PubMed ID: 15557875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.